Safety and effectiveness of percutaneous sclerotherapy for venous disorders of the labia majora in patients with vascular malformations

Brill, Richard; Deistung, Andreas; Gussew, Alexander; Goldann, Constantin; Stangl, Franz; Uller, Wibke; Rosendahl, Jonas; Wildgruber, Moritz; Wohlgemuth, Walter A.

doi:10.1016/j.jvsv.2020.01.008

Cited by 4 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be due to the shorter time interval (3–6 months) between the two MRI scans. In this study the time between the initial MRI and the follow-up Imaging amounted to an average of 44,9 months (2–95 months) (Brill et al 2020 ). What both studies have in common, however, is that (almost) complete obliteration of sfMs was observed in individual cases.…”

Section: Discussionmentioning

confidence: 83%

“…ethanol 1.2,1–5). Nakamura et al indicate a significantly higher range of interventions (Ali and Mitchell 2017 ; Aronniemi et al 2016 ; Behravesh et al 2016 ; Brill et al 2020 ; Clemens et al 2017 ; Fresa et al 2021 ; Gorman et al 2018 ; Gulsen et al 2011 ; Helm et al 2022 ; Marrocco-Trischitta et al 2001 ), but the average number of interventions (2.6) is in a similar range to the above-mentioned studies. A connection between patient satisfaction and the number of interventions was proven in Nakamura's publication (Nakamura et al 2014 ).…”

Section: Discussionmentioning

confidence: 84%

“…With an average of 1.5 sessions per patient (Ali and Mitchell 2017 ; Aronniemi et al 2016 ; Behravesh et al 2016 ; Brill et al 2020 ), the number of interventions is lower than in many publications. However, as mentioned above, some patients were treated in other centers too.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Results of interventional treatment of peripheral slow-flow malformations

et al. 2023

View full text Add to dashboard Cite

Background In recent years sclerotherapy has increasingly become the treatment of choice for peripheral slow-flow malformations. However, the long-term effectiveness of sclerotherapy is still a matter of debate, especially when it comes to new sclerosing agents like polidocanol. This study aims at gathering further information concerning its long-term effectiveness and safety. Results Most patients reported a reduction of symptoms which include pain (57,7%), swelling (65,4%) and functional impairment (60%). Cosmetic complaints were less likely to be reduced by sclerotherapy (44,4%). In most cases a relief of symptoms was stable for many years, especially after several consecutive treatment sessions. Complication rates were comparably low, with only 2 patients requiring additional treatment at hospital and no lasting damages. (…) (7) Most patients (70,9%) were at least partially satisfied with the treatment. Satisfaction was closely linked to a partial or complete relief of symptoms (p = 0.001). Conclusion Sclerotherapy is a promising way of treating slow-flow-malformations. Polidocanol has proved to be a save sclerosing agent. The reduction of major symptoms was substantial in most cases and lasted for many years.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 84%

See 1 more Smart Citation

Results of interventional treatment of peripheral slow-flow malformations

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Surgery is not the first choice for VM because it has a great impact on the function and morphology of local tissues, and it may cause severe complications. Laser ablation is limited by availability and expertise and is not suitable for deep or complicated lesions (8)(9)(10)(11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

Microwave ablation with hydrodissection used for the treatment of vascular malformations: effectiveness and safety study

Wang,

Lu,

Zhuang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectThe aim of the study was to investigate the safety, effectiveness, and peripheral nerve protection in ultrasound-guided microwave ablation (US-guided-MWA) for vascular malformations (VMs) closely related to peripheral nerve.Materials and methodsFrom August 2019 to February 2022, 31 patients with 39 VMs received US-guided-MWA. All lesions were confirmed to be closely related to the peripheral nerve by imaging evaluation. Hydrodissection was applied to protect surrounding normal tissue, including peripheral nerves. The patients were followed up at 1day, 2 days, 3 days, 1 week, 1 month, 3 months after operation. Measurements of lesion volume, volume reduction ratio (VRR), sensory and functional abnormalities of adjacent nerves, number of treatments, complication details, personal satisfaction, recurrence, and symptom improvement were recorded.ResultsAmong the 39 VMs, the maximum volume is 128.58ml, while the minimum volume is 0.99ml. After a mean follow-up of 13.06 ± 4.83 months, the mean numerical rating scale (NRS) score decreased from 5.13 ± 1.65 to 0.53 ± 0.83 (P<0.0001). The mean mass volume was reduced from 18.34 ± 24.68 ml to 1.35 ± 2.09 ml (P=0.0001). The VRR of all lesions was 92.06%. However, the mean number of treatments was only 1.64 ± 0.87. All patients were satisfied with the technique, with a mean satisfaction score (SC) of 9.23 ± 1.13. There were no motor function abnormalities of the related nerves. 10 patients felt numbness in the ablation area after ablation, and gradually recovered after 1 month.ConclusionUS-guided-MWA serves as a novel alternative approach for patients with VMs. Preoperative evaluation of the relationship between VMs and peripheral nerves combined with intraoperative hydrodissection is an effective and safe method to prevent nerve injury.

show abstract

“…ethanol 1.2; 1-5). Nakamura et al indicate a signi cantly higher range of interventions(1)(2)(3)(4)(5)(6)(7)(8)(9)(10), but the average number of interventions(2.6…”

mentioning

confidence: 99%

Results of interventional treatment of peripheral slow-flow malformations

Altenbernd

Kutta

Forsting

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: In recent years sclerotherapy has increasingly become the treatment of choice for peripheral slow-flow malformations. However, the long-term effectiveness of sclerotherapy is still a matter of debate, especially when it comes to new sclerosing agents like polidocanol. This study aims at gathering further information concerning its long-term effectiveness and safety. Results: Most patients reported a reduction of symptoms which include pain (57,7%), swelling (65,4%) and functional impairment (60%). Cosmetic complaints were less likely to be reduced by sclerotherapy (44,4%). In most cases a relief of symptoms was stable for many years, especially after several consecutive treatment sessions. Complication rates were comparably low, with only 2 patients requiring additional treatment at hospital and no lasting damages. Previous studies indicate that a volume reduction immediately after treatment is the norm. However, our study suggests that these effects might not be permanent. Most patients (70,9%) were satisfied with the treatment. Satisfaction was closely linked to a partial or complete relief of symptoms (p=0.001). Conclusion: Sclerotherapy is a promising way of treating slow-flow-malformations. Polidocanol has proved to be a save sclerosing agent. The reduction of major symptoms was substantial in most cases and lasted for many years.

show abstract

Safety and effectiveness of percutaneous sclerotherapy for venous disorders of the labia majora in patients with vascular malformations

Cited by 4 publications

References 18 publications

Results of interventional treatment of peripheral slow-flow malformations

Results of interventional treatment of peripheral slow-flow malformations

Microwave ablation with hydrodissection used for the treatment of vascular malformations: effectiveness and safety study

Results of interventional treatment of peripheral slow-flow malformations

Contact Info

Product

Resources

About